Late Gadolinium Enhancement and the Risk of Ventricular Arrhythmias and Sudden Death in NYHA Class I Patients with Non-Ischaemic Cardiomyopathy
European Journal of Heart Failure · 2023
DOI: 10.1002/ejhf.2793 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Andrea Di Marco und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital Universitari de Bellvitge, Barcelona, Spain. Hauptthemen laut MEDLINE: Heart Failure, Myocardial Ischemia, Defibrillators, Implantable, Cardiomyopathies. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Academy of Medical Sciences, British Heart Foundation.
Abstract (Originalsprache)
Aim
To compare the risk of ventricular arrhythmias (VA) and sudden death (SD) between New York Heart Association (NYHA) class I and NYHA class II–III patients with non-ischaemic cardiomyopathy (NICM). Methods and results Observational retrospective cohort study including patients with NICM who underwent cardiac magnetic resonance at two hospitals. The primary endpoint included appropriate implantable cardioverter defibrillator (ICD) therapies, sustained ventricular tachycardia, resuscitated cardiac arrest and SD. The secondary endpoint included heart failure (HF) hospitalizations, heart transplant, left ventricular assist device implant or HF death. Overall, 698 patients were included, 33% in NYHA class I. During a median follow-up of 31 months, the primary endpoint occurred in 57 patients (8%), with no differences between NYHA class I and NYHA class II–III cases (7% vs. 9%, p = 0.62). Late gadolinium enhancement (LGE) was the only independent predictor of the primary outcome both in NYHA class I and NYHA class II–III patients. LGE+ NYHA class I patients had a similar cumulative incidence of the primary endpoint as compared to LGE+ NYHA class II–III (p = 0.92) and a significantly higher risk as compared to LGE– NYHA class II–III cases (p < 0.001). The risk of the secondary endpoint was significantly higher in patients in NYHA class II–III as compared to those in NYHA class I (hazard ratio 3.2, p = 0.001).
Conclusions
Patients with NICM in NYHA class I are not necessarily at low risk of VA and SD. Actually, LGE+ NYHA class I patients have a high risk. NYHA class I patients with high-risk factors, such as LGE, could benefit from primary prevention ICD at least as much as those in NYHA class II–III with the same risk factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Hospital Universitari de Bellvitge, Barcelona, Spain.
- Bioheart-Cardiovascular Diseases Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, Barcelona, Spain.
- Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
- Department of Cardiology, North West Heart Centre, Manchester University NHS Foundation Trust, Manchester, UK.
- Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
- Wellcome Centre for Cell-Matrix Research, Division of Cell-Matrix Biology & Regenerative Medicine, School of Biology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science…
Förderung
- Academy of Medical Sciences
- British Heart Foundation
Zitieren
APA
Di Marco, A., Brown, P., Mateus, G., Faga, V., Nucifora, G., Claver, E., Viedma, J., Galvan, F., Bradley, J., Dallaglio, P. D., de Frutos, F., Miller, C. A., Comín-Colet, J., Anguera, I., & Schmitt, M. (2023). Late Gadolinium Enhancement and the Risk of Ventricular Arrhythmias and Sudden Death in NYHA Class I Patients with Non-Ischaemic Cardiomyopathy. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2793
Vancouver
Di Marco A, Brown P, Mateus G, Faga V, Nucifora G, Claver E, et al. Late Gadolinium Enhancement and the Risk of Ventricular Arrhythmias and Sudden Death in NYHA Class I Patients with Non-Ischaemic Cardiomyopathy. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2793
BibTeX
@article{DiMarco2023,
author = {Di Marco, Andrea and Brown, Pamela and Mateus, Gemma and Faga, Valentina and Nucifora, Gaetano and Claver, Eduard and Viedma, Jisela and Galvan, Francisco and Bradley, Joshua and Dallaglio, Paolo D and de Frutos, Fernando and Miller, Christopher A and Comín-Colet, Josep and Anguera, Ignasi and Schmitt, Matthias},
title = {Late Gadolinium Enhancement and the Risk of Ventricular Arrhythmias and Sudden Death in NYHA Class I Patients with Non-Ischaemic Cardiomyopathy},
journal = {European Journal of Heart Failure},
year = {2023},
doi = {10.1002/ejhf.2793}
}
EUVIMED